BeyondSpring Inc. (BYSI)
- Previous Close
2.2700 - Open
2.3600 - Bid 2.1000 x 100
- Ask 2.1900 x 100
- Day's Range
2.1200 - 2.3600 - 52 Week Range
0.6530 - 4.0000 - Volume
33,660 - Avg. Volume
223,723 - Market Cap (intraday)
83.103M - Beta (5Y Monthly) 0.17
- PE Ratio (TTM)
-- - EPS (TTM)
-0.7100 - Earnings Date Apr 29, 2024 - May 1, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
1.25
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.
beyondspringpharma.comRecent News: BYSI
Performance Overview: BYSI
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BYSI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BYSI
Valuation Measures
Market Cap
83.10M
Enterprise Value
72.18M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
53.66
Price/Book (mrq)
--
Enterprise Value/Revenue
46.57
Enterprise Value/EBITDA
-2.45
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-38.69%
Return on Equity (ttm)
--
Revenue (ttm)
1.55M
Net Income Avi to Common (ttm)
-27.51M
Diluted EPS (ttm)
-0.7100
Balance Sheet and Cash Flow
Total Cash (mrq)
15.39M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--